Covid-19 News

  • India’s massive COVID surge puzzles scientists

    The pandemic is sweeping through India at a pace that has staggered scientists. Daily case numbers have exploded since early March: the government reported 273,810 new infections nationally on 18 April. High numbers in India have also helped drive global cases to a daily high of 854,855 in the past week, almost breaking a record set in January.

    Just months earlier, antibody data had suggested that many people in cities such as Delhi and Chennai had already been infected, leading some researchers to conclude that the worst of the pandemic was over in the country.

    Researchers in India are now trying to pinpoint what is behind the unprecedented surge, which could be due to an unfortunate confluence of factors, including the emergence of particularly infectious variants, a rise in unrestricted social interactions, and low vaccine coverage. Untangling the causes could be helpful to governments trying to suppress or prevent similar surges around the world.

    European countries such as France and Germany are also currently experiencing large outbreaks relative to their size, and nations including Brazil and the United States are reporting high infection rates at around 70,000 a day. But India’s daily totals are now some of the highest ever recorded for any country, and are not far off a peak of 300,000 cases seen in the United States on 2 January.

    ‘Ripple in a bathtub’

    COVID-19 case numbers started to drop in India last September, after a high of around 100,000 daily infections. But they began to rise again in March and the current peak is more than double the previous one.

    “The second wave has made the last one look like a ripple in a bathtub,” says Zarir Udwadia, a clinician-researcher in pulmonary medicine at P D Hinduja Hospital & Medical Research Centre in Mumbai, who spoke to Nature during a break from working in the intensive-care unit. He describes a “nightmarish” situation at hospitals, where beds and treatments are in extremely short supply.

    Shahid Jameel, a virologist at Ashoka University in Sonipat, agrees that the intensity of the current wave is startling. “I was expecting fresh waves of infection, but I would not have dreamt that it would be this strong,” he says.

  • European countries such as France and Germany are also currently experiencing large outbreaks relative to their size,

    This is wrong. Both countries just live in a fake lock-down period steered by "expert idiots". Both countries are rd by FM/R and completely block the use of alternate treatments. Worst is Germany that in it's thinking and action is close to a fascist state now again. We here (Switzerland) have more infections and will stop the lock down.

    We, Switzerland just found the first P1 mutation... I have to shake my ivermectin now...

  • Switzerland has first death of a teenager (19) with CoV-19. As he was a high risk person it certainly - as in former cases - will turn out that it just was with!

    So the question is why sees Brazil quite many deaths among children. Former Zikka victims? Malaria other hidden infections? I guess they have no budget to find out.

  • Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19…irc_artType_railA_article


    The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.


    We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours after starting organ support in the intensive care unit (ICU), were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight), sarilumab (400 mg), or standard care (control). The primary outcome was respiratory and cardiovascular organ support–free days, on an ordinal scale combining in-hospital death (assigned a value of −1) and days free of organ support to day 21. The trial uses a Bayesian statistical model with predefined criteria for superiority, efficacy, equivalence, or futility. An odds ratio greater than 1 represented improved survival, more organ support–free days, or both.


    Both tocilizumab and sarilumab met the predefined criteria for efficacy. At that time, 353 patients had been assigned to tocilizumab, 48 to sarilumab, and 402 to control. The median number of organ support–free days was 10 (interquartile range, −1 to 16) in the tocilizumab group, 11 (interquartile range, 0 to 16) in the sarilumab group, and 0 (interquartile range, −1 to 15) in the control group. The median adjusted cumulative odds ratios were 1.64 (95% credible interval, 1.25 to 2.14) for tocilizumab and 1.76 (95% credible interval, 1.17 to 2.91) for sarilumab as compared with control, yielding posterior probabilities of superiority to control of more than 99.9% and of 99.5%, respectively. An analysis of 90-day survival showed improved survival in the pooled interleukin-6 receptor antagonist groups, yielding a hazard ratio for the comparison with the control group of 1.61 (95% credible interval, 1.25 to 2.08) and a posterior probability of superiority of more than 99.9%. All secondary analyses supported efficacy of these interleukin-6 receptor antagonists.


    In critically ill patients with Covid-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes, including survival. (REMAP-CAP number, NCT02735707.


    OLYMPIA – The Washington State Department of Agriculture (WSDA) received confirmation yesterday of a test showing evidence of exposure to SARS-CoV-2, the virus that causes COVID-19, in a group of Washington state dogs who were sampled as part of a study by the University of Washington.

    In all, 23 samples tested positive for antibodies to SARS-CoV-2, and while these are the first cases of a pet testing positive in Washington, they are not the first in the U.S., as there have been numerous reports nationally of companion animals testing positive for SARS-CoV-2. The Centers for Disease Control and Prevention (CDC) and the U.S. Department of Agriculture (USDA) both state that there is no evidence that animals play a significant role in spreading the virus to humans.

    “These detections are not a surprise given the other cases reported across the country,” Washington State Veterinarian Dr. Brian Joseph said. “While there is no significant public health risk, we would advise pet owners who are COVID-positive to take measures to protect their pets from the virus.”

    The Washington State Department of Health recommends that people who are ill with COVID-19 and in home isolation avoid direct contact with pets. If possible, a household member should care for pets in the home. If a person with COVID-19 must care for pets or other animals, they should wear a mask and wash their hands before and after interacting with them. If an animal becomes sick, owners should contact a veterinarian.

    The samples tested in this incident were first obtained by UW researchers as part of a study the UW is leading on pets and companion animals from households where humans have tested positive for COVID-19. The COVID-19 and Pets Study began in early 2020 after the pandemic struck Washington and is being done in partnership with the Washington Animal Disease Diagnostic Laboratory (WADDL) at Washington State University.

    “These results indicate that COVID-infected humans are able to transmit the virus to animals living in the same household. While we don’t have evidence that this poses a risk to other humans, we are recommending that COVID-infected persons take steps to reduce the risk of infecting their pets,” said Dr. Peter Rabinowitz, Director of the UW Center for One Health Research and Principal Investigator for the COVID and Pets Study. “We are continuing this study as the human vaccine rollout takes place, and will be seeing whether any change in household transmission occurs.”

    WADDL advised WSDA earlier this month that their lab had found SARS-CoV-2 antibodies in the samples obtained for the UW study, indicating the animals had been exposed to the coronavirus. Last week, those samples were sent to the USDA National Veterinary Service Laboratory (NVSL), which verified WADDL’s results and provided the confirmation to WSDA.

    Visit the CDC’s Covid-19 and Animals webpage for more information on COVID-19 and animals. You can also go to the USDA Animal and Plant Health Inspection Service website for a complete list of animals that have tested positive for SARS-CoV-2.

  • More evidence Covid is seasonal

    Coronavirus live updates: California variant 20% more transmissible, new study finds

    10:12 a.m. California variant 20% more transmissible, new study finds: The L452R spike mutation, which is present in both the California (B.1.429) and Indian (B.1.617) variants of the coronavirus, is 20% more infectious than the common virus and carries higher viral loads, according to a study published by researchers at UCSF, UCB and the California Department of Public Health. The study also found that antibody neutralization is reduced in COVID-19 patients and vaccine recipients. The variant became the dominant source of infection in the state as of Jan. 31.

    2:39 p.m. California has second lowest infection rate in the U.S.: With the seven-day average of new cases at 40.3 per 100,000 people, California has the lowest coronavirus infection rate in the nation behind Hawaii, which has 39.1 cases per 100,000 for the same period. The latest data from the Centers for Disease Control and Prevention shows the overall U.S. average is 135.3 cases, with Michigan at the top of the list with 483 cases per 100,000 people, followed by New Jersey (269.7), Delaware (264.1) and Pennsylvania (248.5).

  • Hmmm.... kinda like I been sayin all along?

    • “Dr. Ozlem Tureci, co-founder and CMO of BioNTech, which developed a Covid vaccine with Pfizer, said she also expects people will need to get vaccinated against the coronavirus annually, like for the seasonal flu”.


  • OLYMPIA – The Washington State Department of Agriculture (WSDA) received confirmation yesterday of a test showing evidence of exposure to SARS-CoV-2, the virus that causes COVID-19, in a group of Washington state dogs who were sampled as part of a study by the University of Washington.

    In Atlanta at the Georgia Aquarium, some otters got COVID-19. The poor things showed some symptoms. They are recovering.…A3I5X5VVGZ7GGKT2IU3WPNLQ/

  • In Atlanta at the Georgia Aquarium, some otters got COVID-19. The poor things showed some symptoms. They are recovering.…A3I5X5VVGZ7GGKT2IU3WPNLQ/

    This seems to be largely overlooked in the pandemic. The virus has infected domestic as well as wild animals giving the virus a huge Reservoir as well as a huge incubator for mutations as well as another new version of sars/cov. Not enough research has looked into this concerning aspect of the pandemic.

  • The search for animals harbouring coronavirus — and why it matters

    Scientists are monitoring pets, livestock and wildlife to work out where SARS-CoV-2 could hide, and whether it could resurge.

    It was the news Sophie Gryseels had been dreading for months. Almost a year into the pandemic, a seemingly healthy wild mink tested positive for SARS-CoV-2 in Utah. No free-roaming animal was known to have caught the virus before, although researchers had been watching for this closely. “It’s happened,” wrote Gryseels, an evolutionary biologist at the University of Antwerp, Belgium, in an e-mail to her colleagues.

    Ever since the coronavirus started spreading around the world, scientists have worried that it could leap from people into wild animals. If so, it might lurk in various species, possibly mutate and then resurge in humans even after the pandemic has subsided.

    That would bring the tale of SARS-CoV-2 full circle, because wild animals probably brought it to humans in the first place. Strong evidence suggests that the virus originated in horseshoe bats (Rhinolophus spp.), possibly hitching a ride on other animals before infecting people1. In the current stage of the pandemic, with hundreds of thousands of confirmed COVID-19 infections every day, people are still driving transmission of SARS-CoV-2. But years from now, when community spread has been suppressed, a reservoir of SARS-CoV-2 in free-roaming animals could become a recalcitrant source of new flare-ups.

    Wild animals are not the only ones to have drawn scrutiny. Studies have shown that SARS-CoV-2 can infect many domesticated and captive creatures, from cats and dogs, to pumas, gorillas and snow leopards in zoos, and farmed mink. Outbreaks in mink farms have already shown that infected animals can pass the virus back to humans.

    Although these cases have raised concerns, researchers are less worried about viral outbreaks in domestic and farmed animals because such eruptions can be kept in check through quarantining, vaccination and culling. If the virus spreads in wild animals, however, it will be much more difficult to control. “Then there is no hope for eradication,” says Gryseels.

    In theory, the virus could evolve as it circulates among animals — possibly in ways that threaten the efficacy of vaccines or make the pathogen more deadly and infectious to people, says Arinjay Banerjee, a coronavirus researcher at McMaster University in Hamilton, Canada. “Not to sound any alarms, but everything we don’t want to see with this virus seems to happen,” he says.

    Over the past year, scientists have tried to ascertain how credible and grave the risks are. Global efforts are under way to survey wildlife and catch spillovers as soon as possible. Researchers are testing animals from homes, zoos, shelters, veterinary clinics, farms and their surroundings. If any positive cases are detected, countries immediately notify the World Organisation for Animal Health (OIE), based in Paris. Scientists have used computational models and studied cells and whole animals to identify the species most vulnerable to infection with SARS-CoV-2.

    In one year, scientists have collected as much data about the susceptibility of different species to SARS-CoV-2 as was accumulated over the past 50 years for influenza, says Martin Beer, a virologist at the Federal Research Institute for Animal Health in Greifswald, Germany.

    Animal infections are rare, and some researchers are reassured by the data collected so far. But others are more cautious. SARS-CoV-2 is known to infect a wide range of animal species (see ‘Animal outbreaks’). This fact, says Gryseels, combined with the large number of infected people, means that, in principle, the virus has had millions of opportunities to jump from people to animals.

    Many of those jumps could be passing under the radar. Wildlife studies are difficult to do, and animal infections have not been a priority for much of the research community. The wild mink that tested positive in Utah “could just be the tip of the iceberg”, says Sarah Hamer, an epidemiologist and veterinarian at Texas A&M University in College Station. “The more we look, the more we might find.”

    Primary suspects

    Early in the pandemic, pigs were top of the watchlist. They are known to incubate other viruses, such as influenza, and they live in huge numbers in close proximity to humans — some 300 million pigs are farmed in China, where the pandemic began. “We are always afraid if pigs are involved,” says Beer.

    Pigs can also host coronaviruses. In 2018, researchers described a new bat coronavirus that had killed some 25,000 pigs in southern China2. And in February 2020, scientists working on SARS-CoV-2 showed that it could enter pig cells through the ACE2 protein — the same receptor that it uses to infect people3.

    But when researchers began artificially infecting pigs and piglets with SARS-CoV-2, they found that it did not replicate well4,5. These studies suggest that pigs are largely resistant to infection with the virus. “Thank goodness, because with the volume of pig production globally, that would have been a huge problem,” says Peter Daszak, president of the non-profit research organization Ecohealth Alliance in New York City.

    With pigs off the priority list, bats became the centre of attention. They are the purported source of SARS-CoV-2, and researchers worried that the virus could spread into new bat populations. In April, the US Fish and Wildlife Service advised scientists to suspend all research that involved capturing and hand-ling bats.

    As with pigs, however, the results of studies into bats have been generally reassuring. A study of ACE2 receptors in the cells of 46 bat species found that the majority were poor hosts6. But controlled experiments have shown that some species, such as fruit bats (Rousettus aegyptiacus), can get infected and spread the infection to other bats5. And, with more than 1,400 species, “bats are more of a black box than other animals”, says Gryseels.

  • COVID Variants Detected in Animals, May Find Hosts in Mice

    By Brenda Goodman, MA…als-may-find-host-in-mice

    March 25, 2021 -- The new coronavirus variants are not just problems for humans.

    New research shows they can also infect animals, and for the first time, variants have been able to infect mice, a development that may complicate efforts to rein in the global spread of the virus.

    In addition, two new studies have implications for pets. Veterinarians in Texas and the United Kingdom have documented infections of B.1.1.7 — the fast-spreading variant first found in the U.K. — in dogs and cats. The animals in the U.K. study also had heart damage, but it's unclear if the damage was caused by the virus or was already there and was found as a result of their infections.

    Animal studies of coronavirus and its emerging variants are urgent, Sarah Hamer, DVM, a veterinarian and epidemiologist in the Texas A&M University's College of Veterinary Medicine and Biomedical Sciences in College Station, says.

    She's part of a network of scientists who are swabbing the pets of people who are diagnosed with COVID-19 to find out how often the virus passes from people to animals.

    The collaboration is part of the CDC’s One Health initiative. One Health aims to tackle infectious diseases by recognizing that people can't be fully protected from pathogens unless animals and the environment are also safeguarded.

    "Over 70% of emerging diseases of humans have their origins in animal populations," Hamer said. "So if we are only focusing on studying disease as it emerges in humans and ignoring where those pathogens have been transmitted or circulating for years, then we might miss the ability to detect early emergence. We might miss the ability to control these diseases before they become problems for human health.”

    Variants Move to Mice

    In new work, researchers at the Institut Pasteur in Paris have shown that the B.1.351 and P.1 variants of concern, which were first identified in South Africa and Brazil, respectively, can infect mice, giving the virus a potential new host.

    Older versions of the virus couldn't infect mice because they weren't able to bind to receptors on their cells. These two variants can.

    On one hand, that's a good thing, because it will help scientists more easily conduct experiments in mice. Before, if they wanted to do an experiment with coronavirus in mice, they had to use a special strain of mouse that was bred to carry human ACE2 receptors on their lung cells. Now that mice can become naturally infected, any breed will do, making it less costly and time-consuming to study the virus in animals.

    On the other hand, the idea that the virus could have more and different ways to spread isn't good news.

    "From the beginning of the epidemic and since human coronaviruses emerged from animals, it has been very important to establish in which species the virus can replicate, in particular the species that live close to humans," said Xavier Montagutelli, DVM, , head of the Mouse Genetics Laboratory at the Institut Pasteur. His study was published as a preprint ahead of peer review on BioRXIV.

  • FLCCC update. WHO and disinformation

    External Content
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • Time to support them,

    FLCCC update. WHO and disinformation

    External Content
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • New Covid variant detected at Texas A&M lab shows signs of antibody resistance and more severe illness in young people…ness-in-young-people.html

    Scientists at Texas A&M University's Global Health Research Complex say they've detected a new Covid-19 variant that shows signs of a more contagious strain that causes more severe illness and appears to be resistant to antibodies.

    The new variant, BV-1, named after its Brazos Valley origin, was found during Texas A&M's routine coronavirus screening via saliva sample in a young student who had mild cold-like symptoms. The student tested positive for Covid on March 5 and tested positive again on March 25, showing that the new strain may cause a longer infection in younger people. The student's symptoms resolved by April 2 and a third test on April 9 came back negative.

    Texas A&M scientists say that cell culture-based experiments from other labs have shown that several neutralizing antibodies had no effect in controlling other variants with the same genetic markers as BV-1.

    "We do not at present know the full significance of this variant, but it has a combination of mutations similar to other internationally notifiable variants of concern," said Texas A&M Chief Virologist Ben Neuman. "This variant combines genetic markers separately associated with rapid spread, severe disease and high resistance to neutralizing antibodies."

  • The virus has infected domestic as well as wild animals giving the virus a huge Reservoir as well as a huge incubator for mutations as well as another new version of sars/cov.

    In new work, researchers at the Institut Pasteur in Paris have shown that the B.1.351 and P.1 variants of concern, which were first identified in South Africa and Brazil, respectively, can infect mice, giving the virus a potential new host.

    The western world only has one infection namely one by the FM/R/J virus. Symptoms: Greed, disgusting human rights, friendships to dictators.

    As long as ivermectin works you only have to worry the FM/R/J mafia for not giving it to you. There is no need for any expensive new crap drug that improves your chances for a few %.

    It's a sign of total madness to develop such crap and write papers about. You have a 1/1000000 chance - at most -to top ivermectin in regard to all relevant factors. Harmless dose, with no side effect, can be produced at lowest cost. Is stable for a long time, works against all virus mutations. Also animals can be treated to clean reservoirs.

    Even Japanese natto beans seem to be good anti virals...And don't forget Sutherlandia that is dirt cheap too.

  • Watch the FLCCC update I posted, kory talks of big pharma influence

  • Do preservative and stray proteins cause rare COVID-19 vaccine side effect?…id-19-vaccine-side-effect

    Researchers in Germany and Canada have added provocative new details to their proposal for how the COVID-19 vaccine made by AstraZeneca might be causing an unusual clotting disorder in a small number of recipients. The mechanism, involving stray human proteins and a preservative in the vaccine, remains speculative. And it is not clear whether their hypothesis explains similar reactions observed in recipients of the COVID-19 vaccine made by Johnson & Johnson (J&J).

    The new data are “interesting but not a smoking gun by any means” for the group’s hypothesis, says Gowthami Arepally, a hematologist at the Duke University School of Medicine who is working as an external consultant with AstraZeneca on the issue. But figuring out what in a COVID-19 vaccine might start the sometimes fatal combination of blood clotting and low platelets is crucial for developing better treatments for the side effect and possibly for understanding who might be most at risk, says Paul Offit, a vaccine researcher at the Children’s Hospital of Philadelphia (CHOP). It could also be vital for modifying vaccines so they don’t kick-start the reaction, which researchers are calling vaccine-induced immune thrombotic thrombocytopenia (VITT).

    Vaccine regulators are struggling to balance the small risk of VITT versus the clear need to immunize people against the pandemic virus SARS-CoV-2. The European Medicines Agency (EMA) declared on Tuesday that the COVID-19 protection of the J&J vaccine significantly outweighs the danger of the rare side effect and recommended its use, with an addition to the warning label that alerts doctors and recipients to the clotting problem. That advice, which matches EMA’s verdict on the AstraZeneca vaccine, cleared the way for vaccinations with the J&J shots to begin across Europe.

    Both J&J and AstraZeneca use modified adenoviruses to deliver and express the spike protein gene of SARS-CoV-2. But new data posted Tuesday in a preprint on Research Square show that doses of the AstraZeneca vaccine also contain significant amounts of protein from human cells—presumably from the human cell line used to grow the virus during the manufacturing process. The preprint’s authors, some whom were among the first to identify the VITT side effect, propose that these proteins, together with another component of the vaccine called ethylenediaminetetraacetic acid (EDTA), may set off a dangerous response by the immune system in some vaccine recipients.

    EDTA is used in some vaccines as a preservative, but it is also known to make blood vessels a bit leaky, says Andreas Greinacher, an expert on clotting at the University of Greifswald who led the study. He said he was suprised at the concentration the group found in the AstraZeneca vaccine samples they examined: 100 micromoles, which is much higher than amounts listed for other common vaccines.

    The group showed that in a mouse model, the vaccine did increase vascular leakage. Greinacher says this may make any free proteins in a vaccine dose more likely to encounter the red blood cell fragments known as platelets, or thrombocytes, in a recipient’s bloodstream. Platelet factor 4 (PF4), a protein secreted by these thrombocytes, could then form complexes with the residual human proteins and other components of the vaccine, thanks to its strong positive charge. Indeed, when the researchers added PF4 to the vaccine in the lab, large complexes formed. Greinacher notes that other vaccines contain human proteins, but the amount—between 70 and 80 micrograms per milliliter (mcg/mL) in the four batches they tested—was “surprisingly high,” he says. Other vaccines list amounts of 5 mcg/mL or less, although many do not specify an amount.

    In a tiny minority of people, Greinacher and his colleagues speculate, the combination of PF4 complexes and the strong inflammation triggered by the vaccine may turn on a specialized set of immune cells that can make antibodies to PF4. (This also happens in a similar clotting syndrome triggered by the blood thinner heparin. In that case, heparin forms the problematic complexes with PF4.) In an even smaller minority, the researchers say, the antibodies to PF4 are strong enough to fuel additional immune reactions in the blood that deplete platelets in the blood and cause potentially deadly clots to form in the brain, abdomen, or lungs.

    Those PF4 antibodies can be useful if the body is fighting off severe infection—but they can get out of control, Greinacher says. “It’s like waking a sleeping dragon,” he says. “In most cases, we really want to keep the dragon sleeping, and the vaccine is like a guy coming into a cave and throwing stones at it.” An AstraZeneca spokesperson said the company could not comment directly on the preprint, but that they “continue to work to understand the individual cases, epidemiology, and possible mechanisms that could explain these rare events.”

    Greinacher has asked J&J for doses of its vaccine so he can analyze its contents and see whether it might trigger the same cascade. The vaccine had not been used yet in Germany, which he says prevented him from using it in his initial experiments.

    Offit notes that other vaccines are grown in cell culture and contain cellular debris, and it isn’t clear that AstraZeneca’s contains more or different remnants. EDTA may also not be needed to trigger VITT; J&J’s COVID-19 vaccine doesn’t include it, for instance. “Adenovirus has a notorious history of being a particularly inflammatory stimulating virus,” says Mortimer Poncz, a pediatric hematologist at CHOP. “Whether the EDTA is involved, I think, is the softest part of the whole story.”

    Arepally agrees. “The virus itself, which has been given in such large amounts, is probably enough to cause an inflammatory response,” she says. Arepally suggests PF4 simply binds to the adenovirus—which could, in theory, be why the J&J vaccine produces the same side effect. She speculates that a few unlucky people “simply have higher levels of PF4 for some reason and that’s why they are forming these complexes when they get the vaccine.”

    Poncz, on the other hand, isn’t convinced PF4 complexes are actually behind the clotting problems. The complexes may be innocent bystanders, he says, although he applauds Greinacher “for leading the field and providing thought-provoking and experiment-provoking questions.”

    Rolf Marschalek, a molecular biologist at Goethe University Frankfurt, suspects that additional spike-related mechanisms may play a role once a vaccinated person’s cells start to make the viral protein, which happens in the same time frame as the clotting disorders appear, generally between 4 to 20 days following vaccination. These might then add to the PF4 antibody cascade which the Greifswald group describes, he says.

    Even as the spotlight shines on the J&J and AstraZeneca vaccines, scrutiny is widening to two other COVID-19 vaccines that rely on adenovirus vectors: Sputnik V, developed by the Russian Gamaleya National Research Institute of Epidemiology and Microbiology, and another made by the Chinese company CanSino Biologics. CanSino CEO Yu Xuefeng told journalists the company is monitoring recipients more carefully after the clotting reports emerged. The Gamaleya Institute said in a press release there had been no reports of clotting disorders following its vaccine rollout it many countries, although it’s not clear how many people have received it so far.

    Hungary is already using Sputnik V, and several other European countries are considering purchases, but EMA has not yet approved it for use. EMA Director Emer Cooke says the agency’s review of safety data for the vaccine “is at an early stage,” and it has not yet looked carefully at data regarding possible side effects. “But now that we are aware of [VITT], will make sure it’s part of the company’s responsibility to report any of these events.”

  • Watch the FLCCC update I posted, kory talks of big pharma influence

    I started to recommend ivermectin may 2020. I'm happy that with only one half year delay now committed professionals take over and confirm all the stuff I did post since one year.

    How corrupt Bill Gates and WHO is and who is the mafia that rapes our world. How corrupt FDA is with e.g. banning horse ivermectin.

    Even this forum does no longer listen this tread to avoid banning from google...

  • Gets C19,Prescribed Ivermectin

    and time for Pizza Party.

    External Content
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.